Advancing Knowledge,
Improving Patient Outcomes

AcademicCME is a jointly accredited healthcare solutions medical education company designed to impact practice behavior by providing clinicians with multi-format educational resources in various therapeutic areas. Our mission is to improve patient outcomes through practical, customized and comprehensive continuing education.

CE Courses

The New Era of Biosimilar Therapeutics for Multiple Sclerosis

This CME program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2024 Course…

Shared Decision-Making and Patient Education to Promote Adherence to DOACs and Continuity of Care in VTE

This 0.5-hour, Whiteboard Animation Webcast is designed to review collaboration with the multidisciplinary healthcare team and the patient to improve shared decision-making and promote adherence to DOACs for patients with VTE…

CAR T Research and Treatment Advances in Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Follicular Cell Lymphoma (FL) Therapies

This CME program will highlight recent advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and follicular cell lymphoma (FL)…

Strategies to Coordinate the Multidisciplinary Team for Secondary Prevention, Long-Term Treatment, and the Assessment of Bleeding Risk

This 0.5-hour, Whiteboard Animation Webcast is designed to review collaboration with the multidisciplinary healthcare team for secondary prevention, long term treatment and bleeding risk assessment for patients with VTE…

Review of Clinical Trial and Real-World Data for DOAC and other Anticoagulation Therapeutics for VTE

This 0.5-hour, Whiteboard Animation Webcast is designed to review clinical trial and deal-world data for DOAC and other anticoagulation therapeutics for VTE…

Update for Hospital and Health-System Pharmacists on Newer Therapeutics to Optimize Management of Patients with Generalized Myasthenia Gravis

About 85% of patients with generalized myasthenia gravis (gMG)–an autoimmune disease of the neuromuscular junction caused by antibodies that attack components of the postsynaptic membrane, impair neuromuscular transmission, and therefore cause weakness and fatigue of skeletal and bulbar muscles–have demonstrable IgG autoantibodies…

Upcoming Events

10th European Stroke Organisation Conference – ESOC 2024

May 15th – 17th, 2024

Texas Neurological Society Summer Meeting

July 19th – 20th, 2024

ESMO Congress 2024

September 13th – 17th, 2024

Alliance Industry Summit 2024

September 16th – 18th, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *